nct_id,title,official_title,overall_status,phase,sponsor,start_date,primary_completion_date,completion_date,first_posted_date,last_update_date,planned_primary_outcomes,planned_secondary_outcomes,results_outcome_measures,results_participant_flow,results_baseline,results_adverse_events,site_count,site_countries,sites_compact,start_year,Pathologic_Complete_Response,Event_Free_Survival,Disease_Free_Survival,Overall_Survival,Best_Overall_Response,Duration_of_Response,Progression_Free_Survival,Overall_Response,Target_Response,Non_target_Response,Symptomatic_Deterioration,Disease_Recurrence,Pathologic_Complete_Response_pCR,Objective_Response_Rate,Time_to_Progression,detected_endpoint_names,planned_endpoint_count,reporting_gap_flag,consort_participant_flow,consort_recruitment,consort_baseline,consort_numbers_analyzed,consort_outcomes_estimation,consort_ancillary_analyses,consort_harms,consort_results_score,HER2_flag,BRCAm_flag,NM_new_medicine,EI_extension_of_indication,nm_ei_explanation,sponsor_class,has_results,completion_year,years_since_completion,multi_country_flag,phase_bucket
NCT02682693,Denosumab as an add-on Neoadjuvant Treatment (GeparX),Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX),COMPLETED,PHASE2,GBG Forschungs GmbH,2017-02-13,2019-12-31,2020-12-31,2016-02-15,2021-02-02,"['pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.', 'pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks']","['To test for interaction of denosumab treatment with RANK expression.', 'To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.']",,,,,1,Germany,"Charité Campus Mitte [Berlin, Germany]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2020.0,5.0,0,Phase 2
NCT03013504,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients with HER2+ Early Breast Cancer",COMPLETED,PHASE3,Prestige Biopharma Limited,2018-02-19,2019-04-19,2022-01-13,2017-01-06,2024-11-06,['total pathological complete response rate (tpCR)'],"['total breast pathological complete response rate (bpCR)', 'Overall response rate (ORR)', 'Overall Survival (OS)', 'Event-free Survival (EFS)', 'Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)', 'Cardiac dysfunction', 'Immunogenecity', 'Clearance (Pharmacokinetic)', 'Area under the curve (AUC, Pharmacokinetic)', 'Plasma half life (Pharmacokinetic)']",,,,,15,Belarus; Bulgaria; Estonia; France; Georgia; Hungary; Italy; Malaysia; Poland; Russia; Spain; Thailand; Ukraine,"Minsk Clinical Oncological Dispensary [Minsk, Belarus] | Complex Oncology Center [Plovdiv, Bulgaria] | East Tallinn Central Hospital [Tallinn, Estonia] | Centre René Huguenin (Institut Curie) [Saint-Cloud, France] | S. Khechinashvili University Hospital [Tbilisi, Georgia] | National Institute of Oncology [Budapest, Hungary] | University of Debrecen [Debrecen, Hungary] | Modena Hospital [Modena, Italy] | Beacon International Specialist Centre [Kuala Lumpur, Malaysia] | Hospital Kuala Lumpur [Kuala Lumpur, Malaysia] | Szpital Specjalistyczny Brzeziny [Brzeziny, Poland] | LLC ""Vitamed"" [Moscow, Russia] | Hospital Universitario Virgen Macarena [Seville, Spain] | Maharaj Nakorn Chiang Mai Hospital [Chiang Mai, Thailand] | GI ""V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine "" [Kharkiv, Ukraine]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial compares HD201, a biosimilar to Herceptin, in patients with HER2+ early breast cancer, indicating an extension of indication for a similar treatment rather than a new medicine.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03128619,"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer","A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer",TERMINATED,PHASE1,Jonsson Comprehensive Cancer Center,2017-08-02,2022-03-31,2022-03-31,2017-04-25,2022-09-26,"['Change in Ki-67 expression defined as the percent of cells staining positive by validated central assay (Phase II)', 'Incidence of dose-limiting toxicities (DLT) evaluated according to National Cancer Institute (NCI) CTCAE version 4.0 to determine MTD (Phase Ib)']","['Clinical objective response rate (ORR) evaluated by RECIST 1.1 using caliper measurements', 'Gene expression and/or biomarker changes', 'Incidence of adverse events (AEs) evaluated according to NCI CTCAE version 4.0', 'pCR rate defined as the percentage of randomized patients with a pCR', 'The pharmacokinetic (PK) parameter - area under the plasma concentration-time curve (AUC) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Elimination half-life (t½) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Maximum plasma concentration (Cmax) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Minimum plasma concentration of BAY 80-694 will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Time when Cmax occurs (Tmax) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Average plasma concentration at steady state (Cavg) will be determined for copanlisib in arms A, B, and escalation dose levels.']",,,,,1,United States,"UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 1
NCT03140553,TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer,TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer,COMPLETED,PHASE2,Guangdong Provincial People's Hospital,2016-09-01,2019-11-11,2019-11-11,2017-05-04,2020-07-28,['pCR'],[],,,,,1,China,"Guangdong General Hospital [Guangzhou, China]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,0,Phase 2
NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,SOLTI Breast Cancer Research Group,2017-07-13,2019-06-10,2019-07-20,2017-08-14,2021-03-17,['Rate of ROR-low according to the Prosigna test.'],"['Tumor Overall response rate (ORR)', 'pCR in the breast and axillary lymph nodes', 'PEPI Score', 'Residual Cancer Burden (RCB)', 'Rate of breast conserving surgery (BCS)', 'Decrease in Ki67 in both treatment arms.', 'Incidence, duration and severity of Adverse Events (AEs)']",,,,,21,Spain,"Hospital Clinic de Barcelona [Barcelona, Spain] | Hospital General de Catalunya [Barcelona, Spain] | Hospital Universitari Vall d' Hebron [Barcelona, Spain] | Institut Català d'Oncologia l'Hospitalet [Barcelona, Spain] | Consorcio Hospitalario Provincial de Castellón [Castelló, Spain] | Hospital San Pedro de Alcántara [Cáceres, Spain] | Fundació Privada Hospital Asil de Granollers [Granollers, Spain] | Centro Integral Oncologico Clara Campal [Madrid, Spain] | Centro Oncológico MD Anderson International España [Madrid, Spain] | Hospital Quirón Madrid [Madrid, Spain] | Hospital Rey Juan Carlos [Madrid, Spain] | Hospital Universitario 12 de octubre [Madrid, Spain] | Hospital Universitario Fundación de Alcorcón [Madrid, Spain] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hospital Universitari Son Espases [Palma, Spain] | Complexo Hospitalario Universitario de Santiago [Santiago de Compostela, Spain] | Hospital Virgen del Rocío [Seville, Spain] | Hospital Virgen Macarena [Seville, Spain] | Fundación Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Hospital Universitari Arnau de Vilanova de València [Valencia, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,0,Phase 2
NCT03272477,Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients,"A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.",COMPLETED,PHASE2,Palleos Healthcare GmbH,2017-10-05,2020-07-14,2024-03-04,2017-09-05,2024-04-17,['Pathological complete response (pCR)'],"['Health-related quality of life using EORTC QBL-BR-23 scale', 'Health-related quality of life using EQ5D-5L scale', 'Health-related quality of life using EORTC QLQ-C30 scale', 'Tumor size reduction by mammography', 'Tumor size reduction by palpation and ultrasound', 'Overall survival', 'Duration of invasive disease-free survival', 'Number of mastectomies', 'Ki67 level', 'cDNA composition']",,,,,1,Germany,"Evangelisches Krankenhaus Bethesda Mönchengladbach [Mönchengladbach, Germany]",2017.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2024.0,1.0,0,Phase 2
NCT03433313,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,"A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer",COMPLETED,PHASE3,"EirGenix, Inc.",2018-10-16,2022-01-20,2022-01-20,2018-02-14,2023-01-20,['Determination of pathologic complete response (pCR) at time of surgery'],"['pCR at the time of surgery', 'pCR at the time of surgery', 'Event-free survival (EFS) up to end of study (EOS)', 'Overall response (OR) prior to surgery', 'Overall survival (OS) up to End of Study (EOS)', 'Incidence of AEs', 'Evaluation of Immunogenicity of EG12014 and Herceptin', 'Measure serum trastuzumab concentration']",,,,,91,Belarus; Chile; Colombia; Georgia; India; Russia; South Africa; South Korea; Taiwan; Ukraine; United States,"Detroit Clinical Research Center [Farmington Hills, United States] | Aultman Hospital, Cancer Center [Canton, United States] | Brest Regional Oncology Center [Brest, Belarus] | Gomel Regional Clinical Oncology Center [Homyel, Belarus] | N.N. Aleksandrov Republican Research Oncology and Medical Radiology Center [Lesnoy, Belarus] | Minsk City Clinical Oncology Center [Minsk, Belarus] | Mogilev Regional Oncology Center [Mogilev, Belarus] | Vitebsk Regional Clinical Oncology Center [Vitebsk, Belarus] | Medical Research Limited Society [Temuco, Chile] | Oncocentro Apys [Viña del Mar, Chile] | Clinic Life Foundation [Medellín, Colombia] | Rodrigo Botero SAS [Medellín, Colombia] | LTD High-Tech Hospital MedCenter [Batumi, Georgia] | JSC ""Evex Hospitals [Kutaisi, Georgia] | LTD Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine [Tbilisi, Georgia] | LTD Aversi Clinic [Tbilisi, Georgia] | LTD Cancer Research Centre [Tbilisi, Georgia] | LTD Health House [Tbilisi, Georgia] | LTD Institute of Clinical Oncology [Tbilisi, Georgia] | LTD S.Khechinashvili University Hospital [Tbilisi, Georgia] | Malkhaz Katsiashvili Multiprofile Emergency Medicine Center [Tbilisi, Georgia] | Cytecare Cancer Hospitals [Bengaluru, India] | King George's Medical University, Department of Endocrine surgery, Shatabdi Phase II [Lucknow, India] | Tata Memorial Centre [Mumbai, India] | HCG NCHRI Cancer Centre [Nagpur, India] | Christian Medical College, Department of Medical Oncology [Vellore, India] | Arkhangelsk Clinical Oncology Center [Arkhangelsk, Russia] | Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center [Chelyabinsk, Russia] | Evimed, LLC [Chelyabinsk, Russia] | Ivanovo Regional Oncology Center [Ivanovo, Russia] | Republican Clinical Oncology Center [Kazan', Russia] | Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center [Krasnoyarsk, Russia] | Kursk Regional Clinical Oncology Center [Kursk, Russia] | N.N. Blokhin National Medical Oncology Research Center [Moscow, Russia] | National Medical Research Center for Radiology [Moscow, Russia] | Vitamed"" LLC [Moscow, Russia] | A.F.Tsyb Medical Radiology Research Center [Obninsk, Russia] | Clinical Oncology Center [Omsk, Russia] | Pyatigorsk Interdistrict Oncology Center [Pyatigorsk, Russia] | Rostov Oncology Research Institute [Rostov-on-Don, Russia] | Regional Clinical Oncology Center [Ryazan, Russia] | AV Medical Group [Saint Petersburg, Russia] | City Clinical Oncology Center [Saint Petersburg, Russia] | Clinic ""Mart"" [Saint Petersburg, Russia] | I.I. Mechnikov North-Western State Medical University [Saint Petersburg, Russia] | Leningrad Regional Oncology Center (Outpatient Department) [Saint Petersburg, Russia] | Leningrad Regional Oncology Center (Surgery Department) [Saint Petersburg, Russia] | N.N. Petrov National Medical Research Center of Oncology [Saint Petersburg, Russia] | Oncology Center of Moskovskiy District [Saint Petersburg, Russia] | Private Medical Institution ""EVROMEDSERVIS"", Department of Oncology [Saint Petersburg, Russia] | St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncology) [Saint Petersburg, Russia] | Republican Oncology Center [Saransk, Russia] | Oncology Center #2 [Sochi, Russia] | Tomsk National Research Medical Center [Tomsk, Russia] | Regional Clinical Oncology Center [Veliky Novgorod, Russia] | Volgograd Regional Clinical Oncology Center [Volgograd, Russia] | GVI Oncology, Cape Gate Oncology Centre [Cape Town, South Africa] | The Oncology Centre [Durban, South Africa] | Medical Oncology Centre of Rosebank [Johannesburg, South Africa] | Little Company of Mary Medical Center, Department of Oncology [Pretoria, South Africa] | University of Pretoria, Department of Medical Oncology [Pretoria, South Africa] | Keimyung University - Dongsan Medical Center [Daegu, South Korea] | Kaohsiung Medical University Chung-Ho Memorial Hospital [Kaohsiung City, Taiwan] | China Medical University Hospital [Taichung, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | Taipei Veterans General Hospital [Taipei, Taiwan] | Tri-Service General Hospital [Taipei, Taiwan] | Linkou Chang Gung Memorial Hospital [Taoyuan District, Taiwan] | Chernihiv Regional Oncology Center [Chernihiv, Ukraine] | Chernivtsi Regional Clinical Oncology Center [Chernivtsi, Ukraine] | Clinical Oncology Center [Dnipro, Ukraine] | Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy [Dnipro, Ukraine] | Prikarpattia Clinical Oncology Center [Ivano-Frankivsk, Ukraine] | Communal Non-profit enterprise ""Regional Center of Oncology"" [Kharkiv, Ukraine] | State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Department of Clinical Oncology and Hematology [Kharkiv, Ukraine] | Khmelnytskyi Regional Oncology Center [Khmelnytskyi, Ukraine] | Kryvyi Rih Oncology Center, Department of Chemotherapy [Kryvyi Rih, Ukraine] | Kyiv City clinical Hospital #2 [Kyiv, Ukraine] | Kyiv Regional Oncology Center, Department of Mastology [Kyiv, Ukraine] | Medical Center ""Verum"" [Kyiv, Ukraine] | Medical Center of First Private Clinic [Kyiv, Ukraine] | Volyn Regional Oncology Center, Department of Chemotherapy [Lutsk, Ukraine] | Public Institution under Lviv Regional Council: Lviv Regional Treatment and Diagnostics Oncology Center, Department of Chemotherapy [Lviv, Ukraine] | Mariupol Oncology Center [Mariupol, Ukraine] | Odesa Regional Clinical Hospital, Center for Mastology, Department of Thoracic Surgery [Odesa, Ukraine] | Odesa Regional Oncology Center [Odesa, Ukraine] | Ternopil Regional Clinical Oncology Center, Department of Chemotherapy [Ternopil, Ukraine] | Central City Clinical Hospital, Department of Oncology and Radiology [Uzhhorod, Ukraine] | Zakarpattia Regional Clinical Oncology Center, Department of Chemotherapy [Uzhhorod, Ukraine] | Podillia Regional Oncology Center [Vinnytsia, Ukraine] | Zhytomyr Regional Oncology Center [Zhytomyr, Ukraine]",2018.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03588091,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,"A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Docetaxel Compared With Placebo Plus Trastuzumab and Docetaxel in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer",COMPLETED,PHASE3,"Jiangsu HengRui Medicine Co., Ltd.",2018-07-24,2024-01-31,2024-01-31,2018-07-17,2025-08-22,['Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by independent review committee(IRC)'],"['Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by sites', 'Event-free survival(EFS)', 'Disease-free Survival (DFS)', 'Distance Disease-free Survival (DDFS)', 'Objective Response Rate (ORR) during neoadjuvant period']",,,,,17,China,"Peking University People's Hospital [Beijing, China] | The Fifth Medical Center of Chinese PLA General Hospital [Beijing, China] | Fujian Medical University Union Hospital [Fuzhou, China] | Sun Yet-Sen University Cancer Center [Guangzhou, China] | Guangdong Provincial People's Hospital [Guangzhou, China] | Sun Yat-sen Memorial Hospital, Sun Yat-sen University [Guangzhou, China] | The Fourth Hospital of Hebei Medical University [Shijiazhuang, China] | The affiliated cancer hospital of Zhengzhou University & Henan Cancer Hospital [Zhengzhou, China] | Huai'an First People's Hospital [Huaian, China] | JiangSu Province Hospital [Nanjing, China] | Shandong Cancer Hospital [Jinan, China] | The Affiliated Hospital Of Qingdao University [Qingdao, China] | Fudan University Shanghai Cancer Center [Shanghai, China] | The Second Affiliated Hospital Of Xi'an Jiaotong University [Xian, China] | The First Affiliated Hospital Zhejiang University School of Medicine [Hangzhou, China] | Zhejiang Cancer Hospital [Hangzhou, China] | The Second Affiliated Hospital Zhejiang University School of Medicine [Hangzhou, China]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2024.0,1.0,0,Phase 3
NCT03680560,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,"A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies",TERMINATED,PHASE1,"Cogent Biosciences, Inc.",2019-03-13,2020-03-12,2020-03-12,2018-09-21,2020-03-31,"['Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values', 'Determination of recommended phase 2 dose (RP2D) regimen']","['Anti-tumor activity as measured by overall response rate (ORR) per iRECIST', 'Anti-tumor activity as measured best overall response (BOR)', 'Anti-tumor activity as measured by duration of response (DOR)', 'Anti-tumor activity as measured by progression-free survival (PFS)', 'Anti-tumor activity as measured by overall survival (OS)', 'Assessment of persistence of ACTR as measured by flow cytometry', 'Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)', 'Assessment of ACTR phenotype and function as measured by flow cytometry', 'Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration', 'Trastuzumab pharmacokinetics (PK)']",,,,,6,United States,"Yale Smilow Cancer Hospital [New Haven, United States] | Miami University Cancer Center [Miami, United States] | The Ohio State University [Columbus, United States] | Sarah Cannon Research Institute/Tennessee Oncology, PLLC [Nashville, United States] | Baylor Scott & White Medical Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03735966,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,"Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer : a Single-arm,Ahead , Open-label Study",COMPLETED,PHASE2,Henan Cancer Hospital,2018-11-20,2020-10-20,2020-10-20,2018-11-08,2022-12-01,['Pathological Complete Response (pCR)'],"['EFS', 'DFS', 'DDFS', 'ORR']",,,,,1,China,"Henan cancer hospital [Zhengzhou, China]",2018.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER_GOV,False,2020.0,5.0,0,Phase 2
NCT03819010,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -","Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery",COMPLETED,PHASE2,MedSIR,2019-05-07,2019-07-30,2019-12-31,2019-01-28,2020-11-27,['Difference on Recurrence Score between pre and post-treatment (molecular results)'],"['Molecular changes', 'Molecular induction', 'Global molecular reduction', 'increase RS result', 'Evaluate the concordance rate between the RCB score (0- I vs. II-III) and the post-treatment RS result in both cohorts of patients after treatment with palbociclib in com-bination with letrozole;', 'Evaluate the concordance rate between the pCR and the post-treatment RS re-sult in both cohorts of patients after treatment with palbociclib in combination with letro-zole;', 'Changes in RS']",,,,,18,Portugal; Spain,"Hospital da Luz [Lisbon, Portugal] | Hospital Fernando Fonseca [Lisbon, Portugal] | Portuguese Institute of Oncology of Oporto [Porto, Portugal] | ICO Badalona [Badalona, Spain] | ICO l'Hospitalet [L'Hospitalet de Llobregat, Spain] | Hospital de Jaén [Jaén, Spain] | Complejo Hospitalario Universitario A Coruña (CHUAC) [A Coruña, Spain] | H. Vall Hebrón [Barcelona, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Reina Sofia [Córdoba, Spain] | Onkologikoa [Donostia / San Sebastian, Spain] | Hospital Arnau de Vilanova [Lleida, Spain] | Hospital Ramón y Cajal [Madrid, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain] | Instituto Valenciano de Oncologia [Valencia, Spain] | Hospital Arnau de Vilanova de Valencia [Valencia, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain] | Hospital Miguel Servet [Zaragoza, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,1,Phase 2
NCT03988036,A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),"A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype",COMPLETED,PHASE2,West German Study Group,2020-08-18,2022-05-31,2022-05-31,2019-06-17,2023-05-15,['Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-HER2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with HER2-enriched early breast cancer assessed by PAM50 testing'],"['Number and percentage of fatal adverse events as assessed by CTCAE 5.0', 'Number and percentage of serious treatment-emergent adverse events as assessed by CTCAE 5.0', 'Number and percentage of treatment-related adverse events as assessed by CTCAE 5.0', 'Number and percentage of treatment-emergent adverse events of interest as assessed by CTCAE 5.0', 'Number and percentage of adverse events leading to investigational product discontinuation', 'Number and percentage of severity of adverse events as assessed by CTCAE 5.0', 'Number and percentage of causality of adverse events as assessed by investigator and sponsor', 'Number and percentage of outcome of adverse events as per investigator assessment', 'Number and percentage of seriousness of adverse events as assessed by CTCAE 5.0']",,,,,12,Germany,"Universitätsklinikum Tübingen Frauenklinik [Tübingen, Germany] | Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern [Munich, Germany] | Rotkreuzklinikum München GmbH Frauenklinik [Munich, Germany] | Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie [Georgsmarienhütte, Germany] | Diakoniekrankenhaus Henriettenstiftung GmbH [Hanover, Germany] | Onkologische Praxis [Bielefeld, Germany] | St. Elisabeth Krankenhaus GmbH Brustzentrum [Cologne, Germany] | Onkodok GmbH [Gütersloh, Germany] | Ev. Krankenhaus Bethesda Brustzentrum Niederrhein [Mönchengladbach, Germany] | Praxisnetzwerk [Troisdorf, Germany] | Charité Campus Mitte Klinik für Gynäkologie [Berlin, Germany] | Mammazentrum Hamburg [Hamburg, Germany]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study evaluates the combination of pembrolizumab with existing treatments (trastuzumab and pertuzumab) in a specific patient population, indicating an extension of indication for pembrolizumab rather than a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04130152,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,Palbociclib in Combination With Letrozole in Patients With Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Residual Disease After Standard Neoadjuvant Chemotherapy (PROMETEO II),COMPLETED,EARLY_PHASE1,SOLTI Breast Cancer Research Group,2019-11-21,2022-01-26,2022-02-24,2019-10-17,2022-10-25,['Complete Cell Cycle Arrest (CCCA)'],"['Residual Cancer Burden (RCB)', 'Residual Cancer Burden (RCB)', 'Pathological complete response (pCR)', 'Incidence, duration and severity of Adverse Events (AEs)']",,,,,8,Spain,"Hospital General de Catalunya [Barcelona, Spain] | ICO Hospitalet [Barcelona, Spain] | Hospital 12 de octubre [Madrid, Spain] | Hospital Universitario Infanta Sofía [Madrid, Spain] | Hospital Virgen de la Victoria [Málaga, Spain] | Hospital Son Espases [Palma de Mallorca, Spain] | Complejo Hospitalario Santiago de Compostela (CHUS) [Santiago de Compostela, Spain] | Hospital Virgen del Rocío [Seville, Spain]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 1
NCT04468113,Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy,"Prospective, Multicenter Registry Study Evaluating the Feasibility of Ultrasound-guided Clipping of Suspicious Intramammary Lesions in Primary Breast Cancer Patients Receiving Neoadjuvant Therapy (Ultra3Detect)",COMPLETED,,Kliniken Essen-Mitte,2020-05-14,2023-03-30,2023-07-30,2020-07-13,2023-11-24,['Sonographic detection rate of clip at the time of surgery after completion of NST'],"['Number of ultrasound-guided clip placements per patient', 'Rate of successful clip placements in the tumor center', 'Visibility of the device (Tumark® Vision) cannula', 'Complications associated with the application of the clip', 'Sonographic detection rate of clips in patients receiving NST', 'Sonographic detection rate of clips in TNBC and HER2+ patients receiving NST', 'Sonographic detection rate of clips in all patients receiving NST and with pCR', 'Sonographic detection rate of clips in patients not receiving NST', 'Intraoperative detection rate of the clip in specimen radiographs', 'Intraoperative detection rate of the clip on specimen utrasound images', 'Proportion of patients requiring preoperative, mammography-guided wire marking', 'Proportion of patients with mammographic verification after sonographic wire-marking', 'Proportion of patients with artifacts caused by clips', 'Number of patients with complete pathological remission']",,,,,1,Germany,"Interdisciplinary Breast Unit, Kliniken Essen-Mitte [Essen, Germany]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2023.0,2.0,0,NA/Other
NCT04496492,Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.,Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer.,COMPLETED,PHASE2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",2016-02-09,2016-02-09,2017-07-06,2020-08-03,2020-08-03,"['Changes in blood oxidant capacity', 'Changes in blood antioxidant capacity', 'Absolute and relative changes in peripheral blood mononuclear cells obtained before and after four weeks of tocotrienol treatment, as detected by 13-colors citofluorimetry analysis', ""Changes of immune-related miRNA levels in patients' serum samples obtained before and after four weeks of tocotrienol treatment, as determined by quantitative real-time PCR analysis"", 'Changes in immune response associated gene levels in preoperative tissue tumor biopsies and in surgical specimens, obtained before and after four weeks of tocotrienol treatment, respectively, as determined by gene expression profiling analysis', 'Changes in serum inflammatory cytokines and growth factor']","['Treatment-induced changes in proliferation/apoptosis, anti-inflammatory and anti-oxidant activity of breast cancer cell lines', 'Changes in expression of tumor proliferation, hormone receptors and HER2']",,,,,1,Italy,"Fondazione IRCCS Istituto Nazionale Tumori [Milan, Italy]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial investigates the use of tocotrienol, a compound derived from annatto, in breast cancer patients, indicating it is a new medicine being tested for a specific condition.",OTHER,False,2017.0,8.0,0,Phase 2
NCT04675827,De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade,"De-Escalation of Adjuvant Chemotherapy in HER2-positive, Estrogen Receptor-negative, Node-negative Early Breast Cancer Patients Who Achieved Pathological Complete Response After Neoadjuvant Chemotherapy and Dual HER2 Blockade",TERMINATED,PHASE2,Jules Bordet Institute,2022-01-17,2024-11-26,2024-11-26,2020-12-19,2024-12-04,['3-year RFS in HER2-enriched subjects who achieve a pCR'],"['3-year RFS in all subjects who achieve a pCR.', '5-year RFS in all subjects who achieve a pCR.', 'pCR (in the overall population)', '3-year RFS (survival rates)', '3-year invasive disease-free survival (iDFS) (survival rates)', '3-year distant disease-free survival (dDFS) (survival rates)', '3-year overall survival (OS) (survival rates)', 'Recurrence-free interval (RFI) (Time)', '5-year RFS (survival rates)', '5-year invasive disease-free survival (iDFS) (survival rates)', '5-year distant disease-free survival (dDFS) (survival rates)', '5-year overall survival (OS)(survival rates)', 'Recurrence-free interval (RFI) (time)', 'Number of participants experiencing an Adverse Event', 'Number of participants experiencing an Serious Adverse Event']",,,,,85,Australia; Belgium; France; Israel; South Korea; Switzerland,"Icon Cancer Centre Wesley [Auchenflower, Australia] | Ballarat Health Services [Ballarat, Australia] | Bendigo Hospital [Bendigo, Australia] | Sunshine Coast University Hospital [Birtinya, Australia] | Box Hill Hospital [Box Hill, Australia] | Chris O'Brien Lifehouse [Camperdown, Australia] | Monash Medical Centre (Clayton) [Clayton, Australia] | Coffs Harbour Health Campus [Coffs Harbour, Australia] | Concord Repatriation General Hospital [Concord, Australia] | Townsville University Hospital [Douglas, Australia] | Lake Macquarie Private Hospital [Gateshead, Australia] | Gosford Hospital [Gosford, Australia] | Royal Brisbane and Women's Hospital [Herston, Australia] | Icon Cancer Centre Hobart [Hobart, Australia] | Liverpool Hospital [Liverpool, Australia] | Peter MacCallum Cancer Centre [Melbourne, Australia] | Sir Charles Gairdner Hospital [Nedlands, Australia] | Macquarie University [North Ryde, Australia] | Mater Hospital [North Sydney, Australia] | Sunshine Hospital [Saint Albans, Australia] | Calvary Mater Newcastle [Waratah, Australia] | Westmead Hospital [Westmead, Australia] | Princess Alexandra Hospital [Woolloongabba, Australia] | GZA Ziekenhuisen Campus Sint-Augustinus - Iridium Kankernetwerk [Antwerp, Belgium] | OLV ziekenhuis [Aalst, Belgium] | Cliniques Universtaires Saint-Luc [Brussels, Belgium] | Institut Jules Bordet [Brussels, Belgium] | Grand Hôpital de Charleroi [Charleroi, Belgium] | Heilig Hartziekenhuis [Lier, Belgium] | Centre Hospitalier Chretien MontLegia [Liège, Belgium] | CHU UCL Namur Sainte-Elisabeth [Namur, Belgium] | Institut de Cancérologie de l'Ouest - Angers [Angers, France] | Institut Sainte Catherine [Avignon, France] | Centre Hospitalier de la Côte Basque [Bayonne, France] | CHRU Jean Minjoz [Besançon, France] | Institut Bergonié [Bordeaux, France] | Polyclinique Bordeaux Nord Aquitaine [Bordeaux, France] | CHU Morvan [Brest, France] | Centre François Baclesse [Caen, France] | Centre Jean Perrin [Clermont-Ferrand, France] | Centre Georges François Leclerc [Dijon, France] | Hopital Michallon [Grenoble, France] | Centre Oscar Lambret [Lille, France] | CHU de Limoges [Limoges, France] | GHBS Lorient [Lorient, France] | Centre Léon Bérard [Lyon, France] | Institut Paoli Calmettes [Marseille, France] | CH Annecy Genevois [Metz-Tessy, France] | Centre de Cancerologie du Grand Montpellier [Montpellier, France] | Hopital privé du Confluent [Nantes, France] | Groupe Hospitalier Diaconesses Croix Saint-Simon [Paris, France] | Hopital Tenon [Paris, France] | Institut Curie - Paris [Paris, France] | CH Perpignan [Perpignan, France] | Hopital Lyon Sud [Pierre-Bénite, France] | CHU Poitiers [Poitiers, France] | Institut Godinot [Reims, France] | Centre Henri Becquerel [Rouen, France] | Institut Curie - Saint-Cloud [Saint-Cloud, France] | Clinique Saint Anne [Strasbourg, France] | Institut Claudius Regaud [Toulouse, France] | Institut Gustave Roussy [Villejuif, France] | Sheba Medical Center [Ramat Gan, Israel] | Soon Chun Hyang University Cheonan Hospital [Cheonan, South Korea] | Keimyung University Dongsan Hospital [Daegu, South Korea] | National Cancer Center [Goyang-si, South Korea] | Gachon University Gil Medical Center [Incheon, South Korea] | Inha University Hospital [Incheon, South Korea] | Seoul National University Bundang Hospital [Seongnam, South Korea] | CHA bundang Medical Center [Seongnam-si, South Korea] | Asan Medical Center [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Korea university anam hospital [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Seoul ST. Mary's Hospital [Seoul, South Korea] | Severance Hospital [Seoul, South Korea] | Ajou University Hospital [Suwon, South Korea] | Ulsan University Hospital [Ulsan, South Korea] | Hirslanden Klinik - Tumor Zentrum [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitatsspital Basel [Basel, Switzerland] | Kantonsspital Frauenfeld/Frauenklinik [Frauenfeld, Switzerland] | Hopital Daler - Centre du Sein [Fribourg, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland]",2022.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2024.0,1.0,1,Phase 2
NCT04836520,SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.,"Single-arm, Single-center, PhaseⅡ Clinical Study of SHR6390 Combined With Anastrozole for Preoperative Treatment of Hormone Receptor Positive and HER2 Negative Early or Locally Advanced Breast Cancer.",COMPLETED,PHASE2,Tianjin Medical University Cancer Institute and Hospital,2021-08-02,2023-02-28,2023-03-31,2021-04-08,2023-04-12,"['Changes in Ki67 scores', 'RCB (0-1) after surgery']","['Objective response rate (ORR) evaluated by the investigator', 'tpCR', 'Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v5.0 (CTCAE)']",,,,,1,China,"TianJin Medical University Cancer Institute and Hospital [Tianjin, China]",2021.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves SHR6390, which is being tested in combination with Anastrozole for a specific treatment of breast cancer, indicating it is a new medicine.",OTHER,False,2023.0,2.0,0,Phase 2
NCT05931042,Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review,Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review,COMPLETED,,Rawalpindi Medical College,2023-06-01,2023-06-15,2023-06-18,2023-07-05,2023-07-05,['Pathological Complete Response (pCR)'],[],,,,,1,Pakistan,"Rawalpindi Medical University [Rawalpindi, Pakistan]",2023.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2023.0,2.0,0,NA/Other
NCT06040593,Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer,Identify Predictors of Clinical Outcomes in Real-world Patients With HR+ and HER2-low/Negative Breast Cancer Treated With Neoadjuvant Chemotherapy or Endocrine Therapy,COMPLETED,,Daiichi Sankyo,2023-07-31,2023-11-30,2024-02-23,2023-09-15,2024-02-26,"['Event-free survival (EFS) in Participants With HR+ and HER2-Low/Negative Breast Cancer', 'Overall Survival of Participants With HR+ and HER2-Low/Negative Breast Cancer', 'Pathological Complete Response (pCR) in Participants With HR+ and HER2-Low/Negative Breast Cancer']",[],,,,,1,United States,"ConcertAI database [Cambridge, United States]",2023.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2024.0,1.0,0,NA/Other
NCT06149377,"Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer","Application of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer After Neoadjuvant Systemic Therapy: a Multicenter Retrospective Study",COMPLETED,,Fujian Medical University Union Hospital,2012-04-01,2023-05-31,2023-05-31,2023-11-29,2023-12-13,['Axillary pCR'],['the False Negative Rate of SLNB'],,,,,1,China,"Chuan Wang [Fuzhou, China]",2012.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2023.0,2.0,0,NA/Other
NCT06907082,Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice,Prospective Multicenter Observational Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice,COMPLETED,,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,2020-12-28,2024-03-14,2024-03-14,2025-04-02,2025-04-02,['Pathological complete response (pCR) rate'],[],,,,,1,Spain,"HCUVA [Murcia, Spain]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2024.0,1.0,0,NA/Other
